Tysabri and PML: What Current Research Says About Symptom Onset and Progression

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Vigilance to Specific Drug Risk

If you or a loved one is taking Tysabri, you may wonder when PML symptoms might first appear. Recent studies provide a clearer timeline of onset and progression. Building on decades of post-market surveillance and neurological research, this page reviews what current reports reveal about the typical course of PML in Tysabri-treated patients.

Tysabri and PML: A Documented Causal Association

Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn's disease. The drug carries a boxed warning from the U.S. Food and Drug Administration (FDA) regarding an increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri immediately at the first indication of such symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Evidence and Mechanistic Pathway

In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These clinical trial data demonstrate that PML can occur with Tysabri monotherapy or in combination with other immunomodulatory therapies. The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in conditions like multiple sclerosis but also impairs immune surveillance in the brain. The JC virus, which is latent in many individuals, can reactivate and cause PML when immune cells are unable to enter the brain to control the virus. The presence of anti-JCV antibodies indicates prior exposure to the virus and a higher risk of reactivation. Longer treatment duration increases the cumulative immunosuppressive effect, and prior use of immunosuppressants may further compromise immune function.

FDA Warning and Post-Marketing Surveillance

The adequacy of warnings regarding Tysabri and PML is addressed by the FDA's boxed warning, which is the strongest safety warning the agency can issue. The warning clearly states that Tysabri increases the risk of PML and identifies the three known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also instructs healthcare professionals to monitor patients and withhold Tysabri at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The restricted distribution program further ensures that prescribers and patients are informed of the risks. However, despite these warnings, PML remains a serious adverse event that can occur even with appropriate monitoring. For affected patients, causation-related considerations involve establishing a temporal relationship between Tysabri exposure and the development of PML. The timeline between exposure and documented harm can vary. In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing reports indicate that PML can occur at any time during treatment, but the risk increases with longer duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The presence of anti-JCV antibodies and prior immunosuppressant use further stratify risk. Patients who develop PML typically present with progressive neurological symptoms such as cognitive impairment, motor deficits, and visual disturbances. Diagnosis is confirmed by brain imaging and detection of JCV DNA in cerebrospinal fluid. The FDA Adverse Event Reporting System (FAERS) database lists adverse events most frequently associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, and gait disturbance (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not among the most frequently reported events, it is a known and serious risk that is specifically highlighted in the prescribing information. The FAERS data underscore the importance of monitoring for neurological symptoms that could be mistaken for multiple sclerosis relapse but may actually indicate PML.

Causation and Risk Context Summary

In summary, Tysabri is associated with a well-documented risk of PML, as detailed in the FDA boxed warning. The risk is influenced by anti-JCV antibody status, treatment duration, and prior immunosuppressant use. Clinical trial data and post-marketing surveillance confirm the occurrence of PML in treated patients, with a variable timeline from exposure to harm. The warnings provided in the prescribing information are comprehensive, but the severity of PML necessitates ongoing vigilance and prompt action if symptoms arise.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning for Tysabri regarding PML?

The FDA has issued a boxed warning for Tysabri (natalizumab) stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus. The warning instructs healthcare professionals to monitor patients for new signs or symptoms of PML and to withhold Tysabri immediately if PML is suspected (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How does Tysabri cause PML?

Tysabri is a monoclonal antibody that binds to alpha-4 integrins on immune cells, preventing their migration into the brain. This reduces inflammation but also impairs immune surveillance, allowing the JC virus to reactivate and cause PML. The mechanism involves reduced immune control of the virus in the central nervous system.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.